Accéder au contenu
Merck

MLKL trafficking and accumulation at the plasma membrane control the kinetics and threshold for necroptosis.

Nature communications (2020-06-21)
Andre L Samson, Ying Zhang, Niall D Geoghegan, Xavier J Gavin, Katherine A Davies, Michael J Mlodzianoski, Lachlan W Whitehead, Daniel Frank, Sarah E Garnish, Cheree Fitzgibbon, Anne Hempel, Samuel N Young, Annette V Jacobsen, Wayne Cawthorne, Emma J Petrie, Maree C Faux, Kristy Shield-Artin, Najoua Lalaoui, Joanne M Hildebrand, John Silke, Kelly L Rogers, Guillaume Lessene, Edwin D Hawkins, James M Murphy
RÉSUMÉ

Mixed lineage kinase domain-like (MLKL) is the terminal protein in the pro-inflammatory necroptotic cell death program. RIPK3-mediated phosphorylation is thought to initiate MLKL oligomerization, membrane translocation and membrane disruption, although the precise choreography of events is incompletely understood. Here, we use single-cell imaging approaches to map the chronology of endogenous human MLKL activation during necroptosis. During the effector phase of necroptosis, we observe that phosphorylated MLKL assembles into higher order species on presumed cytoplasmic necrosomes. Subsequently, MLKL co-traffics with tight junction proteins to the cell periphery via Golgi-microtubule-actin-dependent mechanisms. MLKL and tight junction proteins then steadily co-accumulate at the plasma membrane as heterogeneous micron-sized hotspots. Our studies identify MLKL trafficking and plasma membrane accumulation as crucial necroptosis checkpoints. Furthermore, the accumulation of phosphorylated MLKL at intercellular junctions accelerates necroptosis between neighbouring cells, which may be relevant to inflammatory bowel disease and other necroptosis-mediated enteropathies.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Millipore
Nucléase Benzonase®, ≥250 units/μL, ≥90% (SDS-PAGE), recombinant, expressed in E. coli, buffered aqueous glycerol solution
Millipore
Membrane Immobilon®-P en PVDF, 1 roll, 27 cm x 3.75 m, 0.45 µm pore size, Hydrophobic PVDF Transfer Membrane for western blotting.
Sigma-Aldrich
Sérum d'âne
Sigma-Aldrich
Iodure de propidium, ≥94.0% (HPLC)
Sigma-Aldrich
Cycloheximide solution, Ready-Made Solution, microbial, 100 mg/mL in DMSO, Suitable for cell culture
Sigma-Aldrich
Cytochalasine B, ≥98% (HPLC), powder
Millipore
Membrane Immobilon®-FL en PVDF, 1 roll, 27 cm x 3.75 m, 0.45 µm pore size, Hydrophobic PVDF Transfer Membrane with low background fluorescence for Western blotting. Compatible with visible and infrared fluorescent probes.
Sigma-Aldrich
Triton X-100, laboratory grade
Sigma-Aldrich
MG-132, A cell-permeable, potent, reversible proteasome inhibitor (Ki = 4 nM).
Sigma-Aldrich
Nocodazole, ≥99% (TLC), powder
Sigma-Aldrich
Anticorps anti-glycéraldéhyde-3-phosphate déshydrogénase, clone 6C5, clone 6C5, Chemicon®, from mouse
Sigma-Aldrich
Chlorpromazine hydrochloride, ≥98% (TLC)
Sigma-Aldrich
Leptomycin B solution from Streptomyces sp., ≥95% (HPLC), Supplied in methanol: water (7:3)
Sigma-Aldrich
Vincristine sulfate salt, 95.0-105.0% (HPLC), powder or crystals
Sigma-Aldrich
Pitstop 2, ≥98% (HPLC)
Sigma-Aldrich
Bréfeldine A, from Penicillium brefeldianum, Ready Made Solution, 10 mg/mL in DMSO
Sigma-Aldrich
Anticorps anti-MLKL, clone 3H1, clone 3H1, from rat
Sigma-Aldrich
MLKL Inhibitor, Necrosulfonamide, MLKL Inhibitor, Necrosulfonamide, CAS 432531-71-0, is a cell-permeable inhibitor that covalently modifies Cys88 and blocks human MLKL adaptor function.
Sigma-Aldrich
ML-7, powder
Sigma-Aldrich
Lectine de Triticum vulgaris (blé), biotin conjugate, lyophilized powder
Sigma-Aldrich
ML 141, ≥98% (HPLC)
Sigma-Aldrich
Golgicide A, ≥98% (HPLC)
Sigma-Aldrich
AM6545, ≥98% (HPLC)
Sigma-Aldrich
Exo 1, ≥98% (HPLC), solid